In summary our results in an experimental model of CM and in patients with uncomplicated falciparum malaria suggest that PPARγ agonists are a promising adjunctive therapy for CM that may improve survival and prevent long-term neurocognitive impairment, and support the testing of PPARγ agonists in patients with CM. Here, PPARG is linked to Plasmodium falciparum malaria.